Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the market ...